Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis

• Status: Unknown status
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective study consisting in testing whether systematic use of aspirin is beneficial for primary prevention of vascular access for hemodialysis attested by doppler ultrasound exam. The investigators will study aspirin resistance in the population of patients undergoing hemodialysis. The investigators will test sensibility of resistant patients to aspirin dose escalation. PFA-100 is the biologic test used in this study to define aspirin resistance.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tunis University
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• dialysed patients

• vascular access aged less than one year

• no serious complication of the vascular access previously such as hemorrhagic complication and tight stenosis

Exclusion Criteria:

• pregnant and breastfeeding women

• patients receiving at baseline other antiaggregant or anticoagulant

• patient not allowed to be treated by aspirin

• systolic blood pressure> 200 mmhg

• diastolic blood pressure>115 mmhg

• liver failure